Patents by Inventor Laurence Harbige
Laurence Harbige has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10576086Abstract: The present invention relates to interferon-gamma (IFN-?) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-? production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 10, 2016Date of Patent: March 3, 2020Assignee: UNIVERSITY OF GREENWICHInventors: Laurence Harbige, Michael Leach
-
Publication number: 20180169105Abstract: The present invention relates to interferon-gamma (IFN-?) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-? production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 10, 2016Publication date: June 21, 2018Inventors: Laurence HARBIGE, Michael LEACH
-
Patent number: 9862691Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.Type: GrantFiled: July 5, 2016Date of Patent: January 9, 2018Assignee: University of GreenwichInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Karl Franzmann
-
Publication number: 20160311784Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.Type: ApplicationFiled: July 5, 2016Publication date: October 27, 2016Applicant: University of GreenwichInventors: Michael LEACH, Laurence HARBIGE, Dieter RIDDALL, Karl FRANZMANN
-
Patent number: 9422253Abstract: A method of treating a disorder such as epilepsy, multiple sclerosis, glaucoma and uveitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia, or trigeminal autonomic cephalalgias. The method includes administering to a subject in need thereof substituted 1,2,4-triazine compounds of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.Type: GrantFiled: February 6, 2014Date of Patent: August 23, 2016Assignee: UNIVERSITY OF GREENWICHInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Karl Franzmann
-
Patent number: 9000155Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: in which R1 is a halo-alkyl group and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system, or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: April 30, 2014Date of Patent: April 7, 2015Assignee: University Of GreenwichInventors: Michael Leach, Karl Franzmann, Dieter Riddall, Laurence Harbige
-
Publication number: 20140243343Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: in which R1 is a halo-alkyl group and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system, or a pharmaceutically acceptable salt or solvate thereof.Type: ApplicationFiled: April 30, 2014Publication date: August 28, 2014Applicant: University of GreenwichInventors: Michael Leach, Karl Franzmann, Dieter Riddall, Laurence Harbige
-
Patent number: 8748600Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when R1 is hydrogen or ?NH when R1 is a substituent group; R3 and R4 are both carbocyclic, heterocyclic or alkyl groups and may be same or different; and R5 is hydrogen, alkyl or a cyclic aryl group, with the proviso that: when R3 and R4 are both alkyl they are linked to form a cycloalkyl group, and R5 is a cyclic aromatic group; and when R3 and R4 are both carbocyclic or heterocyclic groups, R5 is hydrogen or an alkyl group; or a salt thereof.Type: GrantFiled: July 8, 2010Date of Patent: June 10, 2014Assignee: University of GreenwichInventors: Michael Leach, Karl Franzmann, Dieter Riddall, Laurence Harbige
-
Patent number: 8748599Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl group; and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system; or a salt thereof.Type: GrantFiled: July 8, 2010Date of Patent: June 10, 2014Assignee: University Of GreenwichInventors: Michael Leach, Karl Franzmann, Dieter Riddall, Laurence Harbige
-
Publication number: 20140155403Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.Type: ApplicationFiled: February 6, 2014Publication date: June 5, 2014Applicant: University of GreenwichInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Karl Franzmann
-
Patent number: 8691818Abstract: Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or ?NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflType: GrantFiled: January 16, 2009Date of Patent: April 8, 2014Assignee: University Of GreenwichInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Karl Franzmann
-
Publication number: 20130005732Abstract: Compounds of formula (I): especially where R1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R1 is an aralkyl or heterocyclyl-alkyl are disclosed.Type: ApplicationFiled: September 13, 2012Publication date: January 3, 2013Applicant: University of GreenwichInventors: Michael LEACH, Laurence HARBIGE, Dieter RIDDALL, Paul BARRACLOUGH
-
Patent number: 8268823Abstract: Compounds of formula (I) especially where R1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R1 is an aralkyl or heterocyclyl-alkyl are disclosed.Type: GrantFiled: July 13, 2007Date of Patent: September 18, 2012Assignee: University of GreenwichInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Paul Barraclough
-
Publication number: 20120135992Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl group; and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system; or a salt thereof.Type: ApplicationFiled: July 8, 2010Publication date: May 31, 2012Applicant: University of GreenwichInventors: Michael Leach, Karl Franzmann, Dieter Riddall, Laurence Harbige
-
Publication number: 20120135993Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when R1 is hydrogen or ?NH when R1 is a substituent group; R3 and R4 are both carbocyclic, heterocyclic or alkyl groups and may be same or different; and R5 is hydrogen, alkyl or a cyclic aryl group, with the proviso that: when R3 and R4 are both alkyl they are linked to form a cycloalkyl group, and R5 is a cyclic aromatic group; and when R3 and R4 are both carbocyclic or heterocyclic groups, R5 is hydrogen or an alkyl group; or a salt thereof.Type: ApplicationFiled: July 8, 2010Publication date: May 31, 2012Applicant: University of GreenwichInventors: Michael Leach, Karl Franzmann, Dieter Riddall, Laurence Harbige
-
Publication number: 20110009413Abstract: Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or ?NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflType: ApplicationFiled: January 16, 2009Publication date: January 13, 2011Applicant: UNIVERSITY OF GREENWICHInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Karl Franzmann
-
Publication number: 20090291954Abstract: Compounds of formula (I) especially where R1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R1 is an aralkyl or hetero-cyclyl-alkyl are disclosed.Type: ApplicationFiled: July 13, 2007Publication date: November 26, 2009Applicant: University of GreenwichInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Paul Barraclough